Form4insider filings, from the source

SEC Form 3 · accession 0000947871-16-001005

SCICLONE PHARMACEUTICALS INC · SCLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Period of report
Feb 22, 2016
Accepted (ET)
Mar 2, 2016 · 9:24 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, par value $0.001 per share ("Common Stock")F1holding———8,888D
Common StockF1holding———8,888IThrough Dragon Alpha LP
Common StockF1holding———8,888IThrough Dragon Alpha LP and Jade Park Investments Limited

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

Remarks

In connection with the announcement made by the Issuer on February 4, 2016 regarding initiating a process (the "Process") to identify, examine and consider a range of strategic alternatives available to the Issuer, Jade Park, GL Capital Management GP Limited, Bank of China Group Investment Limited and ABG Management Limited (collectively, the "Sponsors") entered into a consortium agreement, pursuant to which the Sponsors agreed to cooperate and proceed in good faith to participate in the Process and/or the transaction contemplated under the Process. Pursuant to Section 13(d)(3) of the Securities Exchange Act of 1934, Dragon Alpha, Jade Park, Mr. Liu and the other Sponsors and certain of their respective affiliates may, based on the facts described in this paragraph, be considered to be a "group", but each of Dragon Alpha, Jade Park and Mr. Liu individually owns less than 10% of the shares of Common Stock of the Issuer and other members of the group do not have a pecuniary interest in any shares of Common Stock owned by Dragon Alpha, Jade Park and Mr. Liu.